Novartis COX-2 is Prexige
Novartis' COX-189 brand name is Prexige (lumiracoxib). An NDA filing for the COX-2 inhibitor is planned for late 2002 (1"The Pink Sheet" Nov. 12, 2001, p. 32)...
You may also be interested in...
Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.